Publication

Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study

Kimmoun, A., Cotter, G., Davison, B., Takagi, K., Addad, F., Celutkiene, J., Chioncel, O., Solal, A. C., Diaz, R., Damasceno, A., Duengen, H-D., Filippatos, G., Goncalvesova, E., Merai, I., Metra, M., Ponikowski, P., Privalov, D., Sliwa, K., Sani, M. U., Voors, A. A., Shogenov, Z. & Mebazaa, A., Nov-2019, In : European Journal of Heart Failure. 21, 11, p. 1459-1467 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Kimmoun, A., Cotter, G., Davison, B., Takagi, K., Addad, F., Celutkiene, J., ... Mebazaa, A. (2019). Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. European Journal of Heart Failure, 21(11), 1459-1467. https://doi.org/10.1002/ejhf.1575

Author

Kimmoun, Antoine ; Cotter, Gad ; Davison, Beth ; Takagi, Koji ; Addad, Faouzi ; Celutkiene, Jelena ; Chioncel, Ovidiu ; Solal, Alain Cohen ; Diaz, Rafael ; Damasceno, Albertino ; Duengen, Hans-Dirk ; Filippatos, Gerasimos ; Goncalvesova, Eva ; Merai, Imad ; Metra, Marco ; Ponikowski, Piotr ; Privalov, Dmitry ; Sliwa, Karen ; Sani, Mahmoud Umar ; Voors, Adriaan A. ; Shogenov, Zaur ; Mebazaa, Alexandre. / Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF) : rationale and design for a multicentre, randomized, parallel-group study. In: European Journal of Heart Failure. 2019 ; Vol. 21, No. 11. pp. 1459-1467.

Harvard

Kimmoun, A, Cotter, G, Davison, B, Takagi, K, Addad, F, Celutkiene, J, Chioncel, O, Solal, AC, Diaz, R, Damasceno, A, Duengen, H-D, Filippatos, G, Goncalvesova, E, Merai, I, Metra, M, Ponikowski, P, Privalov, D, Sliwa, K, Sani, MU, Voors, AA, Shogenov, Z & Mebazaa, A 2019, 'Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study', European Journal of Heart Failure, vol. 21, no. 11, pp. 1459-1467. https://doi.org/10.1002/ejhf.1575

Standard

Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF) : rationale and design for a multicentre, randomized, parallel-group study. / Kimmoun, Antoine; Cotter, Gad; Davison, Beth; Takagi, Koji; Addad, Faouzi; Celutkiene, Jelena; Chioncel, Ovidiu; Solal, Alain Cohen; Diaz, Rafael; Damasceno, Albertino; Duengen, Hans-Dirk; Filippatos, Gerasimos; Goncalvesova, Eva; Merai, Imad; Metra, Marco; Ponikowski, Piotr; Privalov, Dmitry; Sliwa, Karen; Sani, Mahmoud Umar; Voors, Adriaan A.; Shogenov, Zaur; Mebazaa, Alexandre.

In: European Journal of Heart Failure, Vol. 21, No. 11, 11.2019, p. 1459-1467.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J et al. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. European Journal of Heart Failure. 2019 Nov;21(11):1459-1467. https://doi.org/10.1002/ejhf.1575


BibTeX

@article{f9a1eea1d2ec4fe69f29d545febc73d4,
title = "Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study",
abstract = "Aims Patients admitted for acute heart failure (HF) are at high risk of readmission and death, especially in the 90 days following discharge. We aimed to assess the safety and efficacy of early optimization of oral HF therapy with beta-blockers (BB), angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) or angiotensin receptor-neprilysin inhibitors (ARNi), and mineralocorticoid receptor antagonists (MRA) on 90-day clinical outcomes in patients admitted for acute HF. Methods In a multicentre, randomized, open-label, parallel-group study, a total of 900 patients will be randomized in a 1:1 ratio to either 'usual care' or 'high-intensity care'. Patients enrolled in the usual care arm will be discharged and managed according to usual clinical practice at the site. In the high-intensity care arm, doses of oral HF medications - including a BB, ACEi or ARB, and MRA - will be up-titrated to 50{\%} of recommended doses before discharge and to 100{\%} of recommended doses within 2 weeks of discharge. Up-titration will be delayed if the patients develop worsening symptoms and signs of congestion, hyperkalaemia, hypotension, bradycardia, worsening of renal function or significant increase in N-terminal pro-B-type natriuretic peptide between visits. The primary endpoint is 90-day all-cause mortality or HF readmission. Conclusions STRONG-HF is the first study to assess whether rapid up-titration of evidence-based guideline-recommended therapies with close follow-up in a large cohort of patients discharged from an acute HF admission is safe and can affect adverse outcomes during the first 90 days after discharge. Clinical Trial Registration: NCT03412201.",
keywords = "Acute heart failure, Biomarker, Cardiovascular mortality, Rehospitalization, 2013 ACCF/AHA GUIDELINE, ESC GUIDELINES, MORTALITY, EUROQOL, HOSPITALIZATION, MANAGEMENT, DIAGNOSIS, BIOMARKER",
author = "Antoine Kimmoun and Gad Cotter and Beth Davison and Koji Takagi and Faouzi Addad and Jelena Celutkiene and Ovidiu Chioncel and Solal, {Alain Cohen} and Rafael Diaz and Albertino Damasceno and Hans-Dirk Duengen and Gerasimos Filippatos and Eva Goncalvesova and Imad Merai and Marco Metra and Piotr Ponikowski and Dmitry Privalov and Karen Sliwa and Sani, {Mahmoud Umar} and Voors, {Adriaan A.} and Zaur Shogenov and Alexandre Mebazaa",
year = "2019",
month = "11",
doi = "10.1002/ejhf.1575",
language = "English",
volume = "21",
pages = "1459--1467",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Wiley",
number = "11",

}

RIS

TY - JOUR

T1 - Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF)

T2 - rationale and design for a multicentre, randomized, parallel-group study

AU - Kimmoun, Antoine

AU - Cotter, Gad

AU - Davison, Beth

AU - Takagi, Koji

AU - Addad, Faouzi

AU - Celutkiene, Jelena

AU - Chioncel, Ovidiu

AU - Solal, Alain Cohen

AU - Diaz, Rafael

AU - Damasceno, Albertino

AU - Duengen, Hans-Dirk

AU - Filippatos, Gerasimos

AU - Goncalvesova, Eva

AU - Merai, Imad

AU - Metra, Marco

AU - Ponikowski, Piotr

AU - Privalov, Dmitry

AU - Sliwa, Karen

AU - Sani, Mahmoud Umar

AU - Voors, Adriaan A.

AU - Shogenov, Zaur

AU - Mebazaa, Alexandre

PY - 2019/11

Y1 - 2019/11

N2 - Aims Patients admitted for acute heart failure (HF) are at high risk of readmission and death, especially in the 90 days following discharge. We aimed to assess the safety and efficacy of early optimization of oral HF therapy with beta-blockers (BB), angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) or angiotensin receptor-neprilysin inhibitors (ARNi), and mineralocorticoid receptor antagonists (MRA) on 90-day clinical outcomes in patients admitted for acute HF. Methods In a multicentre, randomized, open-label, parallel-group study, a total of 900 patients will be randomized in a 1:1 ratio to either 'usual care' or 'high-intensity care'. Patients enrolled in the usual care arm will be discharged and managed according to usual clinical practice at the site. In the high-intensity care arm, doses of oral HF medications - including a BB, ACEi or ARB, and MRA - will be up-titrated to 50% of recommended doses before discharge and to 100% of recommended doses within 2 weeks of discharge. Up-titration will be delayed if the patients develop worsening symptoms and signs of congestion, hyperkalaemia, hypotension, bradycardia, worsening of renal function or significant increase in N-terminal pro-B-type natriuretic peptide between visits. The primary endpoint is 90-day all-cause mortality or HF readmission. Conclusions STRONG-HF is the first study to assess whether rapid up-titration of evidence-based guideline-recommended therapies with close follow-up in a large cohort of patients discharged from an acute HF admission is safe and can affect adverse outcomes during the first 90 days after discharge. Clinical Trial Registration: NCT03412201.

AB - Aims Patients admitted for acute heart failure (HF) are at high risk of readmission and death, especially in the 90 days following discharge. We aimed to assess the safety and efficacy of early optimization of oral HF therapy with beta-blockers (BB), angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) or angiotensin receptor-neprilysin inhibitors (ARNi), and mineralocorticoid receptor antagonists (MRA) on 90-day clinical outcomes in patients admitted for acute HF. Methods In a multicentre, randomized, open-label, parallel-group study, a total of 900 patients will be randomized in a 1:1 ratio to either 'usual care' or 'high-intensity care'. Patients enrolled in the usual care arm will be discharged and managed according to usual clinical practice at the site. In the high-intensity care arm, doses of oral HF medications - including a BB, ACEi or ARB, and MRA - will be up-titrated to 50% of recommended doses before discharge and to 100% of recommended doses within 2 weeks of discharge. Up-titration will be delayed if the patients develop worsening symptoms and signs of congestion, hyperkalaemia, hypotension, bradycardia, worsening of renal function or significant increase in N-terminal pro-B-type natriuretic peptide between visits. The primary endpoint is 90-day all-cause mortality or HF readmission. Conclusions STRONG-HF is the first study to assess whether rapid up-titration of evidence-based guideline-recommended therapies with close follow-up in a large cohort of patients discharged from an acute HF admission is safe and can affect adverse outcomes during the first 90 days after discharge. Clinical Trial Registration: NCT03412201.

KW - Acute heart failure

KW - Biomarker

KW - Cardiovascular mortality

KW - Rehospitalization

KW - 2013 ACCF/AHA GUIDELINE

KW - ESC GUIDELINES

KW - MORTALITY

KW - EUROQOL

KW - HOSPITALIZATION

KW - MANAGEMENT

KW - DIAGNOSIS

KW - BIOMARKER

U2 - 10.1002/ejhf.1575

DO - 10.1002/ejhf.1575

M3 - Article

VL - 21

SP - 1459

EP - 1467

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 11

ER -

ID: 97455839